Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children

被引:70
作者
Haralambous, E
Hibberd, ML
Hermans, PWM
Ninis, N
Nadel, S
Levin, M
机构
[1] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Paediat, Fac Med, London W2 1PG, England
[2] St Marys Hosp, Paediat Intens Care Unit, London, England
[3] Univ Rotterdam, Med Ctr, Erasmus MC, Sophia Childrens Hosp,Dept Paediat, Rotterdam, Netherlands
关键词
plasminogen-activator-inhibitor-1; meningococcal; sepsis; pediatric; genetics; severity;
D O I
10.1097/01.CCM.0000100122.57249.5D
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective. Meningococcal sepsis invariably is associated with coagulopathy. We have previously reported an association between mortality rate in meningococcal disease and the functional 4G/5G promoter polymorphism of the plasminogen-activator-inhibitor (PAI)-1 gene in a small patient cohort. In a much larger cohort, we aimed to confirm these results and further investigate the role of the 4G/5G polymorphism in determining susceptibility, outcome, and complications of disease. Design: Susceptibility was investigated in two separate studies, a case-control study and a family-based transmission study, each test using a separate patient cohort. Severity was investigated using clinical diagnosis, the presence of vascular complications, Pediatric Risk of Mortality (PRISM)-predicted morality, and actual mortality. Setting. University hospital and laboratories. Subjects: Subjects were 510 UK pediatric patients, 210 parents of patients, and 155 UK Caucasian controls. Interventions., DNA extraction and 4G/5G PAI-1 genotyping was carried out using published techniques. Measurements and Main Results: Predicted mortality distribution differed significantly between genotypes (p = .05) with a significantly higher median PRISM in the 4G/4G (41.1%) than the 4G/5G (23.4%) and 5G/5G (19.0%) genotyped patients combined (p = .02). Actual mortality rate was significantly associated with both genotype (chi-square = 14.8, p = .001) and allele frequencies (chi-square = 14.0, p < .0001), with more deaths in the 4G/4G (28.4%) than the 4G/5G and 5G/5G genotyped patients combined (14.9%; chi-square = 7.9; p = .005; risk ratio, 1.9; 95% confidence interval, 1.2-3.0). Logistic regression indicated a 40% and 91% reduction in the odds of dying if a patient was either 4G/5G or 5G/5G, respectively, in comparison to a 413 homozygous patient. When analyzed by clinical diagnosis, the association with death was found only in the sepsis group (chi-square = 18.7, p < .0001; risk ratio, 2.7; 95% confidence interval, 1.6-4.6). In survivors of disease, a significantly higher proportion of 4G/4G patients suffered from vascular complications (chi-square = 6.7, p = .03; risk ratio, 2.4; 95% confidence interval, 1.1-5.0). The 4G/5G polymorphism was not associated or linked with susceptibility (case-control result, p = .6; family-based transmission study results, p = .2). Conclusions. This study confirms that Caucasian pediatric patients carrying the functional PAI-1 4G/4G genotype are at an increased risk of developing vascular complications and dying from meningococcal disease.
引用
收藏
页码:2788 / 2793
页数:6
相关论文
共 55 条
[1]   LIMULUS ANTILIPOPOLYSACCHARIDE FACTOR PROTECTS RABBITS FROM MENINGOCOCCAL ENDOTOXIN-SHOCK [J].
ALPERT, G ;
BALDWIN, G ;
THOMPSON, C ;
WAINWRIGHT, N ;
NOVITSKY, TJ ;
GILLIS, Z ;
PARSONNET, J ;
FLEISHER, GR ;
SIBER, GR .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (03) :494-500
[2]   TISSUE-TYPE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN DIABETES-MELLITUS [J].
AUWERX, J ;
BOUILLON, R ;
COLLEN, D ;
GEBOERS, J .
ARTERIOSCLEROSIS, 1988, 8 (01) :68-72
[3]  
AZNAR J, 1988, BRIT HEART J, V59, P535
[4]   PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs [J].
Balta, G ;
Altay, C ;
Gurgey, A .
AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (02) :89-93
[5]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[6]   INTERLEUKIN-1 (IL-1) INDUCES BIOSYNTHESIS AND CELL-SURFACE EXPRESSION OF PROCOAGULANT ACTIVITY IN HUMAN VASCULAR ENDOTHELIAL-CELLS [J].
BEVILACQUA, MP ;
POBER, JS ;
MAJEAU, GR ;
COTRAN, RS ;
GIMBRONE, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 160 (02) :618-623
[7]   PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND INHIBITOR-2, ALPHA-2-ANTIPLASMIN, PLASMINOGEN, AND ENDOTOXIN LEVELS IN SYSTEMIC MENINGOCOCCAL DISEASE [J].
BRANDTZAEG, P ;
JOO, GB ;
BRUSLETTO, B ;
KIERULF, P .
THROMBOSIS RESEARCH, 1990, 57 (02) :271-278
[8]   COMPLEMENT ACTIVATION AND ENDOTOXIN LEVELS IN SYSTEMIC MENINGOCOCCAL DISEASE [J].
BRANDTZAEG, P ;
MOLLNES, TE ;
KIERULF, P .
JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (01) :58-65
[9]   THE QUANTITATIVE ASSOCIATION OF PLASMA ENDOTOXIN, ANTITHROMBIN, PROTEIN-C, EXTRINSIC PATHWAY INHIBITOR AND FIBRINOPEPTIDE-A IN SYSTEMIC MENINGOCOCCAL DISEASE [J].
BRANDTZAEG, P ;
SANDSET, PM ;
JOO, GB ;
OVSTEBO, R ;
ABILDGAARD, U ;
KIERULF, P .
THROMBOSIS RESEARCH, 1989, 55 (04) :459-470
[10]  
Brandtzaeg P., 1995, Meningococcal disease, P71